Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

ALEC - Alector, Inc. So'nggi Yangiliklar | Finranks

Home

ALEC

A

Alector, Inc. (ALEC)

NMS – Real vaqt narxi. Valyuta: USD

2.00

-0.12 (-5.66%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

2.00

0.00 (0.00%)

Bozordan keyin: Mar 27, 2026, 4:10 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Alector (ALEC)'s Technical Outlook is Bright After Key Golden Cross

Alector (ALEC)'s Technical Outlook is Bright After Key Golden Cross

After reaching an important support level, Alector, Inc. (ALEC) could be a good stock pick from a technical perspective. ALEC recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles

Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles

Three health-technology names are drawing fresh analyst attention this week as strategic partnerships and business pivots reframe the risk-reward calculus for each.

Alector, Inc. (ALEC) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Alector, Inc. (ALEC) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Alector, Inc. (ALEC) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Alector (ALEC) Reports Q4 Loss, Beats Revenue Estimates

Alector (ALEC) Reports Q4 Loss, Beats Revenue Estimates

Alector (ALEC) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.02 per share a year ago.

Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid antibody for Alzheimer's Disease), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's Disease) and AL064 (ABC-enabled Tau siRNA for Alzheimer's Disease) Independent interim futility analysis of the PROGRESS-AD Phase 2 trial of nivisnebart (AL101) in early Alzheimer's disease expected in the first half of 2026 $256.0 million in cash, cash equivalents and investments provide runway at least through 2027 SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today reported fourth quarter and full year 2025 financial results and recent portfolio and business updates.

Alector to Participate in the TD Cowen 46th Annual Health Care Conference

Alector to Participate in the TD Cowen 46th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a corporate presentation at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 3:10 pm ET.

INVESTOR ALERT: Levi & Korsinsky is Investigating Alec Stock After its Phase 3 INFRONT-3 Clinical Trial Misses Co-Primary Endpoint

INVESTOR ALERT: Levi & Korsinsky is Investigating Alec Stock After its Phase 3 INFRONT-3 Clinical Trial Misses Co-Primary Endpoint

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Alector, Inc. (NASDAQ: ALEC) following the Company's announcement of topline results from its Phase 3 INFRONT-3 trial, evaluating latozinemab in individuals with frontotemporal dementia due to a gene mutation (FTD-GRN). Investors with concerns about Alec's biotech operations may click here for more information.

Videolar

No Data

There is no data to display